NEW YORK (GenomeWeb News) – Pfizer has tapped Cellartis to help it develop an in vitro screening model for predicting toxicity of new chemical entities in humans.
 
Cellartis said Tuesday that the collaboration gives Pfizer access to its human Embryonic Stem cell technology to develop the screening system, for which Cellartis will receive an upfront fee and research funding, and it will hold the rights to sub-license, use, and sell the toxicity screening model.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.